JAK2 and acute myeloid leukemia: Immunotherapy, BCL2, Aurora kinases, Menin, JAK2 inhibitors represent some of the exciting target drugs, investigated in clinical and preclinical trials, which could probably overcome FLT3i resistance and give a breakthrough in the future treatment of FLT3mut AML.